Eutropics Pharmaceuticals

Eutropics Pharmaceuticals, founded in 2008 and based in Cambridge, USA, is pioneering a novel class of functional companion diagnostics (CDx) in oncology. The company's core technology, the PRIMABS-Dx platform, uses conformation-specific antibodies to detect protein-protein interactions (PPIs) within the BCL-2 family, a key regulator of apoptosis. This approach measures 'mitochondrial priming,' a functional state of a tumor cell that predicts its vulnerability to drugs like venetoclax, offering a solution beyond genetic markers. Eutropics is initially targeting hematologic malignancies like AML, where a lack of predictive biomarkers leads to high first-line treatment failure rates.

PRIMABS-Dx platform uses proprietary conformation-specific antibodies (PRIMABS) to detect heterodimeric protein complexes (e.g., BCL-2:BIM) that represent mitochondrial priming. This functional biomarker platform predicts tumor cell vulnerability to apoptosis-inducing therapies (e.g., BH3 mimetics) and is compatible with flow cytometry and IHC.

Eutropics operates in the functional companion diagnostics space, which is less crowded than genomic CDx. Potential competitors include other companies developing BH3 profiling assays (e.g., functional precision medicine tests) and advanced multi-omic profiling approaches. Its primary competition is the current standard of care, which often lacks any predictive biomarker for many targeted therapies.